Melbourn promotes Derek Solomon

Moves from laboratory manager to operations director

Melbourn Scientific, a UK provider of analytical and formulation contract research services for the pharma and biotech industries, is broadening its management team with the promotion of laboratory manager Derek Solomon to the new role of operations director.

Solomon joined Melbourn Scientific in 2005 and has overseen the expansion of the services portfolio, which included the recent addition of clinical manufacture to its formulation development services.

You may also like

Research & Development

Intertek acquires Melbourn Scientific

Combines advanced capabilities for measuring device/drug interaction with OINDP drug characterisation expertise
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

A finite resource: helium

Although helium may be the second most abundant element in the universe, here on earth this noble gas is rare and precious. In the pharmaceutical industry helium is used for cryogenic cooling of magnets used for MRI and in gas chromatography
Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Subscribe now